Who to call at GondolaBio, and when
Fundz watches for the moments GondolaBio starts buying, and tells you who to reach.
- An alert the day GondolaBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GondolaBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GondolaBio. With Fundz connected, it knows.
GondolaBio and Children’s Tumor Foundation Partner to Enhance Neurofibromatosis Type 1 Program Development.
Contract Type
partnership
Description
GondolaBio announced a partnership with the Children’s Tumor Foundation to advance its neurofibromatosis type 1 (NF1) program. The partnership will leverage CTF's expertise and perspectives to ensure patient needs are prioritized in the program's development.
Other recent agreements in Therapeutics and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621. (October 25, 2026)
- Genmab and Incyte collaborate on a colorectal cancer trial using petosemtamab and a mutation-targeting drug. (October 24, 2026)
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
- BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026)
- Prothena Partners with Roche to Advance Prasinezumab for Parkinson's Disease Treatment. (October 20, 2026)
Related People
Agreement Insights
What this usually meansGondolaBio signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.